Chronic lymphocytic leukemia: planning for an aging population

References

• Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood111(12), 5446–5456 (2008).
   PubMed Web of Science ®Google Scholar
• Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J. Natl Cancer Inst.91(10), 861–868 (1999).
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med.343(24), 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood107(3), 885–891 (2006).
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol.25(7), 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet370(9583), 230–239 (2007).
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized Phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood114, 535 (2009).
   PubMed Web of Science ®Google Scholar
• Gribben JG. How I treat CLL up front. Blood115(2), 187–197 (2010).
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood112(4), 975–980 (2008).
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Bennett FL, O’Connor SJ et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med.359(6), 575–583 (2008).
   PubMed Web of Science ®Google Scholar
• Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer80(7), 1273–1283 (1997).
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk. Lymphoma49(1), 49–56 (2008).
   PubMed Web of Science ®Google Scholar
• Else M, Smith AG, Cocks K et al. Patients’ experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. Br. J. Haematol.143(5), 690–697 (2008).
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S et al. First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood114(16), 3382–3391 (2009).
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood106(8), 2912–2919 (2005).
   PubMed Web of Science ®Google Scholar
• de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J. Clin. Epidemiol.56(3), 221–229 (2003).
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol.16(4), 1582–1587 (1998).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Balducci L, Aapro M. Geriatric oncology: a field coming of age. J. Clin. Oncol.25(14), 1821–1823 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Wildiers H, Chatelut E et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J. Clin. Oncol.25(14), 1832–1843 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur. J. Cancer43(1), 14–34 (2007).
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol.27(4), 498–503 (2009).
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol.28(10), 1749–1755 (2010).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Wendtner CM, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin. Lymphoma Myeloma Leuk.10(1), 21–27 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood111(11), 5291–5297 (2008).
   PubMed Web of Science ®Google Scholar